BRTX vs RGEN vs ICLR vs TECH

For growth investors, BioRestorative Therapies, Inc.

(BRTX) is the stronger pick with 175. 0% revenue growth year-over-year, versus 2. 0% for ICON Public Limited Company (ICLR). ICON Public Limited Company (ICLR) offers the better valuation at 13. 1x trailing P/E (10. 5x forward), making it the more compelling value choice. Analysts rate Repligen Corporation (RGEN) a "Buy" — based on 23 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, ICON Public Limited Company (ICLR) is the cheapest at 13.

1x versus Repligen Corporation at 147. 0x. On forward P/E, ICON Public Limited Company is actually cheaper at 10. 5x.

Over the past 5 years, Repligen Corporation (RGEN) delivered a total return of -32.

7%, compared to -99. 4% for BioRestorative Therapies, Inc. (BRTX). Over 10 years, the gap is even starker: RGEN returned +369. 1% versus BRTX's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Bio-Techne Corporation (TECH) is the lower-risk stock at 1.

41β versus BioRestorative Therapies, Inc. 's 2. 21β — meaning BRTX is approximately 56% more volatile than TECH relative to the S&P 500. On balance sheet safety, Bio-Techne Corporation (TECH) carries a lower debt/equity ratio of 23% versus 38% for ICON Public Limited Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), BioRestorative Therapies, Inc.

(BRTX) is pulling ahead at 175. 0% versus 2. 0% for ICON Public Limited Company (ICLR). On earnings-per-share growth, the picture is similar: Repligen Corporation grew EPS 287. 0% year-over-year, compared to -56. 2% for Bio-Techne Corporation. Over a 3-year CAGR, BRTX leads at 105. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ICON Public Limited Company (ICLR) is the more profitable company, earning 9.

6% net margin versus -22. 4% for BioRestorative Therapies, Inc. — meaning it keeps 9. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ICLR leads at 13. 3% versus -28. 8% for BRTX. At the gross margin level — before operating expenses — BRTX leads at 93. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, ICON Public Limited Company (ICLR) trades at 10.

5x forward P/E versus 64. 3x for Repligen Corporation — 53. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TECH: 36. 2% to $69. 33.

In this comparison, TECH (0.

6% yield) pays a dividend. BRTX, RGEN, ICLR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Bio-Techne Corporation (TECH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (0.

6% yield, +112. 5% 10Y return). BioRestorative Therapies, Inc. (BRTX) carries a higher beta of 2. 21 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TECH: +112. 5%, BRTX: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: BRTX is a small-cap high-growth stock; RGEN is a small-cap high-growth stock; ICLR is a small-cap deep-value stock; TECH is a small-cap quality compounder stock. TECH pays a dividend while BRTX, RGEN, ICLR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.